Background-Heart failure is a growing cause of morbidity and mortality. Cardiac phosphatidylinositol 3-kinase signaling promotes cardiomyocyte survival and function, but it is paradoxically activated in heart failure, suggesting that chronic activation of this pathway may become maladaptive. Here, we investigated the downstream phosphatidylinositol 3-kinase effector, serum-and glucocorticoid-regulated kinase-1 (SGK1), in heart failure and its complications. Methods and Results-We found that cardiac SGK1 is activated in human and murine heart failure. We investigated the role of SGK1 in the heart by using cardiac-specific expression of constitutively active or dominant-negative SGK1. Cardiac-specific activation of SGK1 in mice increased mortality, cardiac dysfunction, and ventricular arrhythmias. The proarrhythmic effects of SGK1 were linked to biochemical and functional changes in the cardiac sodium channel and could be reversed by treatment with ranolazine, a blocker of the late sodium current. Conversely, cardiac-specific inhibition of SGK1 protected mice after hemodynamic stress from fibrosis, heart failure, and sodium channel alterations.
bidity and mortality in industrialized nations. Heart failure is associated with altered electric properties of cardiomyocytes 1, 2 including prolongation of action potential duration (APD). These changes, in combination with cardiac structural changes, are termed electric remodeling and comprise the triggers and substrates of ventricular arrhythmia, an important cause of sudden cardiac death. Electric remodeling frequently occurs in association with adverse mechanical remodeling and cardiac dysfunction. In heart failure, an increase in persistent sodium current (late I Na or I NaL ) 1 can contribute to APD prolongation, although the pathways leading to I NaL are incompletely understood. Thus, our understanding of electric and mechanical remodeling in heart disease remains incomplete.
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Acute activation of phosphatidylinositol 3-kinase signaling promotes cardiomyocyte survival and function. [3] [4] [5] Surpris-ingly, proximal phosphatidylinositol 3-kinase signaling is enhanced in patients with cardiac dysfunction and heart failure, 6, 7 raising the possibility that initially compensatory activation of this pathway becomes maladaptive and contributes to adverse remodeling. In this context, serum-and glucocorticoid-regulated kinase-1 (SGK1) is a particularly intriguing candidate. SGK1 is a phosphatidylinositol 3-kinase-dependent, serine-threonine kinase that is structurally similar to Akt. 8 SGK1 expression is transcriptionally regulated by mineralocorticoid signaling, 9 an important contributor to heart failure and arrhythmia. SGK1 regulates sodium ion transport in the kidney 10 and in heterologous expression systems, 11 and thus could mechanistically link phosphatidylinositol 3-kinase signaling, heart failure, and arrhythmia.
We previously found that cardiac SGK1 is activated early after pressure overload induced by transverse aortic constriction (TAC) and that acute activation promotes cardiomyocyte survival. 5 Here we demonstrate that SGK1 is also persistently activated in TAC-induced heart failure (TAC-HF) in mice, and in human heart disease, as well. To examine the functional role of chronic SGK1 activation, we generated cardiacspecific gain-and loss-of-function models through expression of constitutively active (CA) and dominant negative (DN) SGK1 mutants. 8 SGK1 activation comparable to that seen in failing hearts is sufficient to induce hallmarks of mechanical and electric remodeling. Interestingly, aspects of adverse remodeling could be reversed by ranolazine, suggesting a key role for the sodium current in the phenotype of the SGK1-CA transgenic mice. Conversely, genetic SGK1 inhibition mitigated the development of heart failure and fibrosis after TAC, and abrogated heart failure-associated biochemical changes in the sodium channel. Together these data suggest an important role for SGK1 in both the adverse electrical and mechanical remodeling seen in heart failure.
Methods

Generation of SGK1-CA and SGK1-KD Mice
All studies were approved by Institutional Animal Care and Use Committee. HA-tagged CA (S422D) and KD (K127M) mutants of SGK1 were subcloned downstream of the ␣-myosin heavy chain promoter in pbS2SK ϩ (a generous gift from Dr Jeff Robbins, Cincinatti Children's Hospital). Linearized plasmids were microinjected into C57/BL6 oocytes and transferred to pseudopregnant mice as previously described. 12 Three independent lines were identified for each construct.
Transverse Aortic Constriction
Twelve-week-old male mice were subjected to TAC, as previously described with the use of a 25 gauge needle. 13 Perioperative mortality was not different between the wild-type and any of the transgenic lines studied.
Ischemia/Reperfusion Experiments
Twelve-week-old mice were subjected to 30 minutes of left anterior descending artery ligation and 24 hours of reperfusion as previously described. 12 The animals were monitored with continuous telemetry (Scisense data recording) during the time of ischemia and the first 45 minutes of reperfusion or until the animals had recovered from anesthesia.
Ranolazine Pellet Implantation
Two ranolazine pellets (14-day release, 140 mg/pellet, Innovative Research of America) were implanted subcutaneously in the intrascapular region. This dosage and formulation allows for stable plasma therapeutic levels of ranolazine (3-4 mol/L) from 4 days onward after implantation.
Cardiac Function
Echocardiograms were performed on unanesthetized mice by the use of a GE Vivid5 with a 15L8 linear array transducer (13.0 MHz, imaging depth 10 mm) at a frame rate of 166 per second.
Hemodynamic studies were conducted on anesthetized mice (ketamine 100 mg/kg; xylazine 5 mg/kg) by using a 1.5F SciScience PV loop catheter (see online-only Data Supplement Methods).
In Vivo Electrophysiology Studies
Scisense octapolar electrophysiology catheters were advanced via the internal jugular vein to the right heart of mice anesthetized as above. With the use of an OctalBioamp stimulator (Medtronic) and AD data acquisition system, electrophysiology studies were conducted as described. 14 In brief, unipolar and bipolar electrograms were obtained from the right atrium, right ventricle, and left ventricle (LV), amplified, and filtered (event video recorder). Provocative testing was performed with double and triple extrastimulation, and rapid pacing, as well.
Tissue Harvesting
Mice were anesthetized and exsanguinated while the heart was perfusion fixed in situ with 4% paraformaldehyde at 100 cm H 2 O (20 minutes) or removed and cryopreserved in liquid nitrogen for RNA and protein analysis.
Human Studies
Discarded pathological tissues were obtained and studied under an institutional review board-approved protocol.
Protein and RNA Analysis
Cardiac protein lysates were prepared, electrophoresed, and transferred to membranes for immunoblotting as described 15 and used with the following antibodies: total SGK1, p(thr256)SGK1, GSK3␤, p(ser9)GSK3␤, p(ser318)Foxo3A, p(ser253)Foxo3A (all from Cell Signaling); Ryanodine receptor, Nav1.5, Cav1.2a (all from Alomone); NCX (Gene Tex); SERCA (gift from Dr del Monte); SP-19, monoclonal antibody against SCN5a (Sigma); Nedd4-2, phospholamban, p(S16)Phospholamban, caveolin-3, GAPDH, HA tag (ABCAM). Immunoblots were scanned and bands quantified by densitometry. Only samples run on the same gel were compared for quantification.
Immunoprecipitation
Ventricular proteins were prepared in Cell Signaling lysis buffer (1% Triton) supplemented with protease (Thermo Scientific) and phosphatase inhibitors (Roche). Five hundred milligrams of protein was precleared with Protein A/G slurry (Calbiochem), immunoprecipitated with SP-19 (2 mg) or control IgG (3 hours, 4°C). Protein A/G slurry (40 mL) was then added to each tube and nutated for 90 minutes at 4°C. After several washes with phosphate-buffered saline buffer/0.1% Triton X-100 followed by phosphate-buffered saline /protease inhibitors (Thermo Scientific), protein was eluted with Laemmli sample buffer (37°C, 30 minutes), separated by using 4% to 20% gradient sodium dodecyl sulfate-polyacrylamide gel electrophoresis (BioRad), and immunoblotted as above.
SGK1 Kinase Assay
Ventricular proteins (500 mg) were immunoprecipitated with 2 mg of anti-SGK1 antibody (Upstate) with the use of Upstate Catch-and-Release columns. Immunoprecipitates were eluted by using nondenaturing buffer and incubated with 1 mg of SGK1 substrate (GSK3␣/␤ fusion protein, Cell Signaling) and 200 mmol/L ATP (30 minutes, 30°C). Reaction products were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and detected by immunoblotting by using an antibody against phospho-ser 9/21 GSK3␣/␤ (Cell Signaling).
Sucrose Gradient Analysis
Ventricular lysates were subjected to discontinuous sucrose gradient, and heavy membrane pellets, and supernatant fractions, as well, were collected and subjected to immunoblotting by using a modified version of a published protocol 16 (details in online-only Data Supplement Methods).
Histochemistry
Midventricular short axis sections were fixed (4% paraformaldehyde) and 5-mm sections stained with Masson trichrome to visualize fibrosis, wheat germ agglutinin staining to outline cardiomyocytes, and hematoxylin-eosin for cytoarchitecture. A prespecified, genotype-blinded image-selection method with the use of National Institutes of Health SCION software was used to quantify fibrosis (see online-only Data Supplement Methods).
Whole-Cell Patch Clamp Recording
Isolated ventricular myocytes were current and voltage clamped by using the whole-cell patch-clamp configuration as previously described. 17, 18 Voltage and current clamp control and data acquisition are performed with the use of custom-written software (see onlineonly Data Supplement Methods).
Biotin Surface Labeling
Neonatal rat ventricular myocytes were prepared as previously described 5 and plated at 1ϫ10 6 cells/60-mm dish. Cells were grown in serum-containing media (Dulbecco's Modified Eagle's Medium, 10% horse serum, 5% fetal bovine serum, 1% glutamate) for 24 hours, then switched to serum-free media and infected with the indicated adenoviral vectors (multiplicity of infection, 50). After 48 hours, Pierce Cell Surface Protein Isolation Kit (Thermo Scientific) was used. In brief, cells were washed and labeled with Sulfo-NHS-SS-Biotin (30 minutes, 4°C). Cells were then washed and lysed, and biotin-labeled proteins were collected on a Neutravidin-agarose column. After elution, biotin-labeled proteins were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting as above.
Statistics
Unless otherwise specified, data are expressed as meanϮSEM. Distributions for continuous variables within each group were tested for normality by using the D'Agostino and Pearson omnibus normality test or Shapiro-Wilkes normality test if sample size was too small for the D'Agostino and Pearson text. Equality of variance between groups was tested by using the Bartlett test for equal variance. Mean comparisons between 2 groups were compared with the Student t test (normal distribution) or Mann-Whitney (nonnormal distribution) (Prism 5.0d for MAC). For multiple comparisons, 1-way analysis of variance (ANOVA) was performed, followed by the appropriate post hoc test as specified in the figure legends (Stata/IC 11.2 for windows or Prism 5.0d for MAC). For those subgroups with too few numbers to assess normality statistically, we validated parametric tests with appropriate nonparametric tests (Kruskal-Wallis test with post hoc Dunnett multiple comparison test or Mann-Whitney test for comparing 2 groups). For comparisons with 2 crossed factors, we performed 2-way ANOVA with post hoc Bonferroni test for multiple comparisons. In the experiments in which the 2-way ANOVA test could not be performed because of low sample size, we performed multiple t tests with adjustment for multiple comparisons by using a Bonferroni correction. For myocyte experiments, analysis was performed with repeated-measures ANOVA with random effect. Mortality data were quantified by using a Z test of proportions. For experiments with ranolazine in vivo, 2-factor repeated-measures ANOVA was performed; in addition, we also performed paired t tests between the pre and post groups for ranolazine and placebo groups.
Results
Cardiac SGK1 Is Activated in Heart Failure and Diet-Induced Insulin Resistance
We previously found that both activated or phosphorylated (thr-256)-SGK1 (pSGK1) and total SGK1 increase early after TAC-induced pressure overload (TAC). 5 SGK1 activity also remained elevated in chronic models of heart failure following TAC (TAC-HF) ( Figure 1A ). In contrast, neither phospho-nor total SGK1 were altered in a model of exerciseinduced physiological hypertrophy (online-only Data Supplement Figure I) .
To see whether SGK1 is altered in human heart disease, we examined ventricular tissue from patients with hypertensive heart disease (HHD, nϭ7) who died of noncardiac causes, and explants from patients with heart failure and dilated cardiomyopathy (nϭ10) at the time of orthotopic transplantation, as well. Healthy unused donor hearts served as controls (nϭ7). The cohorts were age and sex matched. Coronary angiograms had confirmed the lack of significant epicardial coronary artery disease in the patients with dilated cardiomyopathy, and gravimetry confirmed a trend toward increased LV mass in patients with HHD (control 363Ϯ133 g, HHD 518Ϯ112 g, Pϭ0.07). In HHD hearts, there was an increase in total SGK1 (1.22Ϯ0.12, PϽ0.05) without a change in pSGK1 in comparison with controls ( Figure 1B and 1C ). Dilated cardiomyopathy hearts had a 2.3-fold increase in pSGK1 (2.3Ϯ0.85-fold, PϽ0.005 versus controls) without alterations in total SGK1 ( Figure 1B and 1C) .
These data suggest that SGK1 is abnormally regulated on multiple levels in human heart disease and murine models of hemodynamic stress but not in physiological hypertrophy.
Cardiac-Specific SGK1 Transgenic Mice
To investigate the functional role of SGK1 in the heart, we generated transgenic (TG) mice with cardiac-specific expression of either a CA (S433D) or a DN (K127M) SGK1 mutant 8 driven by the ␣-myosin heavy chain promoter. 19 Two of 3 independent SGK1-CA lines had increased early mortality and could not be maintained. A third line manifested normal viability and stable Mendelian inheritance and was investigated further. Two independent SGK1-DN lines had similar transgene expression and baseline phenotypes, and thus only one of these lines was characterized in detail. Immunoblotting for an incorporated hemagglutinin epitope tag confirmed cardiac-specific expression of both transgenes (online-only Data Supplement Figure IIA ). SGK1 kinase activity was increased in SGK1-CA hearts at baseline to a level comparable to that seen in hearts from mice with TAC-HF (2.3-fold for TAC-HF, 2.9-fold for SGK1-CA TG mice versus wildtype (WT) mice, PϽ0.05 for both; Figure 1A ). SGK1 activity in SGK1-DN hearts was no different from the low level seen in WT at baseline, but the increase in SGK1 kinase activity seen in TAC-HF WT mice was completely blocked in SGK1-DN mice ( Figure 1A ). These activity measurements were further supported by the observation that SGK1-CA increased phosphorylation of an SGK1-specific substrate (Foxo3A Ser-315/318 20 Figure IIB) . Thus, the SGK1-CA mice provide constitutive activation of SGK1 in a pathophysiologically relevant range at baseline, whereas the SGK1-DN mice act as an effective DN blocking the increase in SGK1 activity otherwise seen after TAC.
Gross and microscopic cardiac structure appeared normal in young adult (3-6 months old) SGK1-CA and SGK1-DN mice, including normal heart weight/body weight (HW/BW), head width/total length, and cardiomyocyte size. There was also no increase in fibrosis by Mason-Trichrome staining at these ages (online-only Data Supplement Table I and onlineonly Data Supplement Figure III) . Echocardiography revealed normal left ventricular wall and diastolic chamber dimensions in both SGK1-CA and SGK1-DN TG at these ages. However, fractional shortening was reduced in SGK1-CA mice in comparison with the age-matched WT littermates (WT, 64Ϯ5%; SGK1-CA, 56Ϯ8%; PՅ0.001). SGK1-DN animals had normal function by echocardiography (online-only Data Supplement Table I ). To exclude potential confounding effects of fibrosis and sex, we focused subsequent experiments on 3-to 6-month-old male animals of each genotype.
Invasive hemodynamic studies confirmed that measures of systolic (dP/dt max and preload recruitable stroke work) and diastolic (dP/dt min , g ) function were depressed in SGK1-CA but not SGK1-DN mice (online-only Data Supplement Table  II) . Thus, at baseline, young adult SGK1-CA mice have mild but significant systolic and diastolic dysfunction without overt hypertrophy or fibrosis, whereas the SGK1-DN mice have normal cardiac structure and function.
SGK1 Activation Modulates the Response to TAC
To assess the role of SGK1 activation in the development of heart failure, we subjected SGK1-CA and SGK1-DN mice to TAC. Animals were euthanized either 4 (for SGK1-CA and WT littermates) or 7 weeks (for SGK1-DN and WT littermates) after TAC. The time points were dictated by our Institutional Animal Care and Use Committee policies that require animals be euthanized when they develop severe heart failure. At 4 weeks, TAC induced an increase in HW/BW and wall thickness in both SGK1-CA mice and WT littermates (online-only Data Supplement Figure IVA and IVB). However, SGK1-CA hearts were dilated with thinner walls and markedly reduced function (online-only Data Supplement Figure IVC and IVD). There was a nonsignificant trend toward increased fibrosis in the SGK1-CA in comparison with WT littermates after TAC (online-only Data Supplement Figure IVE ). These data suggest that the baseline cardiac dysfunction seen with chronic SGK1 activation is markedly exacerbated by the additional stress imposed by TAC and accelerates progression to heart failure.
Both WT and SGK1-DN mice tolerated TAC better than SGK1-CA mice, and thus could be monitored longer after the intervention. Seven weeks after TAC, HW/BW ratios and LV wall thickness increased in both SGK1-DN and WT littermates in comparison with sham-operated controls (Figure 2A and 2B), although the change in HW/BW was less marked in SGK1-DN mice (Figure 2A ). Echocardiography 7 weeks after TAC revealed reduced fractional shortening and increased LV dilatation (LV diastolic dimension) in WT but not in SGK1-DN mice ( Figure 2C and 2D ), probably accounting for the differences noted in HW/BW. SGK1-DN mice also had less fibrosis than WT mice after TAC ( Figure 2E ). Thus, SGK1 inhibition protects against the development of heart failure, cardiac dilation, and fibrosis after pressure overload.
Altered Cardiac and Cellular Electrophysiology in SGK1-CA Mice
Because 2 of the 3 SGK1-CA TG lines had increased mortality and SGK1 is known to interact with ion channels, we investigated the electrophysiological effects of chronic SGK1 activation. ECGs in SGK1-CA mice revealed increases in R-wave amplitude, QRS duration, and QTc interval (QTc; 137Ϯ32 in SGK1-CA versus 100Ϯ12 ms in WT; PϽ0.05) without a change in RR or PR intervals (online-only Data Supplement Figure VA ). In addition, spontaneous ventricular tachycardia was noted in a 12-month-old SGK1-CA mouse. SGK1-DN ECGs were not different from WT littermates (online-only Data Supplement Figure VB) and did not manifest ventricular arrhythmias. Holter monitoring for 2 weeks showed a trend toward increased premature ventricular activity, but, because of the sporadic nature of sudden cardiac death, we were not able to correlate mortality with ventricular arrhythmias in the SGK1-CA mice at baseline (online-only Data Supplement Figure VI) .
To provoke ventricular arrhythmia, we performed intracardiac electrophysiological studies with the use of rapid ventricular pacing and programmed ventricular extrastimuli 14 in SGK1-CA, SGK1-DN, and WT littermates. Three of the 6 SGK1-CA mice studied had inducible polymorphic ventricular tachycardia with pacing to 90-ms cycle lengths. In contrast, more aggressive protocols with pacing to 60-ms cycle lengths did not induce ventricular tachycardia in any of the 9 WT and SGK1-DN mice studied (PϽ0.05 by Z test for proportions) ( Figure 3A and 3B) .
The induction of polymorphic ventricular tachycardia with pacing rather than programmed extrastimuli in the absence of significant fibrosis and structural heart disease was suggestive of triggered electric activity. Hence, we next examined the electrophysiological characteristics of cardiomyocytes isolated from SGK1-CA mice. Whole cell patch clamp of cardiomyocytes isolated from 3-to 5-month-old SGK1-CA mice demonstrated action potential prolongation over a range of pacing frequencies (0.5-4 Hz) in comparison with cardiomyocytes from WT littermates ( Figure 3C ). Early and delayed after-depolarizations, a hallmark of triggered electric activity, were also more frequent in SGK1-CA than in WT cardiomyocytes ( Figure 3D ). Thus, the increased ventricular arrhythmia seen in the SGK1-CA mice likely reflects an increase in triggered activity secondary to action potential prolongation. 
Regulation of I Na by SGK1
An increase in APD could be secondary to altered potassium, calcium, or sodium currents. Whole cell patch-clamp analyses of cardiomyocytes isolated from SGK1-CA TG mice or WT littermates showed no differences in the peak potassium or calcium current densities (I to , I K1 , or I Ca, ; online-only Data Supplement Figure VII) . We also observed no difference in major calcium-handling proteins in cardiac sarcoplasmic reticulum or membrane preparations in SGK1-CA mice, with the exception of an increase in the sodium-calcium exchanger (NCX1) (online-only Data Supplement Figure VII) . Overall, these data suggest that altered potassium or calcium currents are unlikely to account for APD prolongation and arrhythmias in SGK1-CA mice.
In contrast, whole cell patch clamp studies revealed substantial changes in sodium currents in SGK1-CA cardiomyocytes. Peak I Na current density manifested a Ϫ10 mV hyperpolarizing shift ( Figure 4A and 4B ), in addition to increased peak current density in comparison with WT cardiomyocytes ( Figure 4C) . No difference was found in the reversal potential of I Na between the SGK1-CA and WT mice cardiomyocytes.
To assess the effect of SGK1 activation on channel gating, we measured voltage-dependent activation and steady-state inactivation of I Na . Cardiomyocytes from SGK1-CA mice showed a hyperpolarizing shift of Ϫ10 mV in the voltage dependence of Na ϩ activation as illustrated in the conductance (G Na ) curves (V 1/2 : Ϫ68.1Ϯ4.0 versus Ϫ58.8Ϯ4.4 mV, PϽ0.001), without altering the slope factor k ( Figure 4D and online-only Data Supplement Table III ). There was also a smaller negative voltage shift of Ϫ5 mV shift in I Na steady-state inactivation in the SGK1-CA in comparison with WT cardiomyocytes (V 1/2 ; Ϫ83.9Ϯ3.6 versus Ϫ77.8Ϯ4.3 mV, PϽ0.05) ( Figure 4D and online-only Data Supplement Table III ). The combination of a large hyperpolarizing shift in the conductance-voltage relationship with a smaller hyperpolarizing shift of the steady-state inactivation leads to an increase in the window current, which would increase Na ϩ conductance over a wider range of membrane potentials. 21, 22 SGK1 activation did not affect recovery from or entry into fast or intermediate inactivation (I IM ) (online-only Data Supplement Figure VIIIA and VIIIB and online-only Data Supplement Table III) . Similarly, neither the fast nor slow time constants of I Na decay were altered by chronic SGK1 activation (online-only Data Supplement Figure VIIIC and online-only Data Supplement Table III) . Figure III) . C, Superimposed action potentials (APs) at CL 0.5 to 4 Hz in WT and SGK1-CA ventricular cardiomyocytes. Inset, APD at 90% repolarization (APD 90 ) was longer in SGK1-CA than in WT ventricular cardiomyopathies. *PϽ0.05 by repeated measures ANOVA. D, Representative EADs or DADs in SGK1-CA myocytes paced at 0.5 Hz. For quantification of EADs/DADs in comparison with WT see Figure 5D . WT indicates wild type; SGK1, serum-and glucocorticoid-regulated kinase-1; DN, dominant negative; CA, constitutively active; VT, ventricular tachycardia; VF, ventricular fibrillation; EAD, early afterdepolarization; DAD, delayed afterdepolarizations; and ANOVA, analysis of variance.
An increase in the persistent Na current, I NaL and increases in window currents have been described in genetic arrhythmia and cardiomyopathy syndromes caused by mutations in the Nav1.5 sodium channel encoded by SCN5a, 23, 24 and in acquired heart failure, as well. 25 SGK1-CA cardiomyocytes displayed a 3.6-fold increase in I NaL in comparison with WT (0.87Ϯ0.29% versus 0.24Ϯ0.13%, PϽ0.01; Figure 5A ). This increase is comparable to that seen with arrhythmogenic SCN5a mutations or acquired heart failure. 25
Alteration of I Na Plays a Key Role in the Phenotype of SGK1-CA TG Mice
To test the functional importance of increased I NaL in SGK1-CA cardiomyocytes, we used ranolazine at low concentrations to selectively block I NaL , without affecting peak I Na . 26 Ranolazine treatment normalized APD in SGK1-CA cardiomyocytes without affecting APD in WT cardiomyocytes ( Figure 5B and 5C ). Moreover, ranolazine treatment reduced the number of SGK1-CA cardiomyocytes with afterdepolarizations (early and delayed after-polarizations) to the background level seen in WT cardiomyocytes ( Figure 5D ). These data strongly suggest that SGK1 activation leads to APD prolongation and increased after-depolarizations primarily through increasing I NaL .
To investigate the role of increased I NaL in this model in vivo, we examined the effects of ranolazine on SGK1-CA TG mice at baseline and in a model of ischemia-reperfusion, in which I NaL has been implicated in ventricular arrhythmias. 27,28 SGK1-CA TG mice had substantially higher mortality (80%) than either WT (24%, Pϭ0.002) or SGK1-DN mice (12.5%, Pϭ0.0006) ( Figure 6A ). Because the majority of SGK1-CA mice were dying in the first hour after reperfusion, we subjected the mice to continuous telemetry during the 30 minutes of ischemia and the first 45 minutes of reperfusion or until the mice had recovered from anesthesia. Interestingly, SGK1-CA mice had a higher incidence of lethal ventricular arrhythmias during ischemia-reperfusion than WT mice (4 of 5 in SGK1-CA versus 0 of 4 in WT, Pϭ0.02) ( Figure 6A and 6B) .
To investigate the role of I NaL in vivo, we implanted ranolazine slow-release pellets subcutaneously in SGK1-CA mice in comparison with placebo pellets ( Figure 6C ). Seven days after implantation, both the QT and QT c intervals were decreased in ranolazine-treated in comparison with placebotreated animals ( Figure 6D) . Remarkably, echocardiography also revealed that fractional shortening was better in ranolazine-treated in comparison with placebo-treated mice ( Figure 6E ). Evaluation of change from baseline fractional shortening by paired t tests demonstrated a nonsignificant trend toward improvement in ranolazine-treated mice (Pϭ0.055) but no difference in placebo-treated animals 05, t test) . D, Superimposed normalized conductance-voltage (G Na -V) and steady-state inactivation curves from WT (E, nϭ6 and ‚, nϭ7, respectively) and SGK1-CA (F, nϭ7 and OE, nϭ9, respectively) cardiomyocytes. There is a significant hyperpolarizing shift noted both in the voltage dependence of activation and steady-state inactivation of I Na in SGK1-CA in comparison with WT. WT indicates wild type; SGK1, serum-and glucocorticoid-regulated kinase-1; and CA, constitutively active.
(Pϭ0.59). The small number of animals in this complex protocol obviously limits the statistical power for such inferences. Nevertheless, these findings are provocative and suggest that the role of SGK1-mediated changes in sodium currents in adverse mechanical remodeling should be addressed more fully in future studies. Finally, ranolazine treatment markedly reduced the incidence of lethal ventricular arrhythmia (1/5) in comparison with either untreated (4/5; Figure 6A ) or placebo-treated SGK1-CA mice (3/3) ( Figure  6F ). Taken together, these data strongly support the hypothesis that increased I NaL is responsible for the ventricular arrhythmia seen in SGK1-CA mice, paralleling our in vitro studies, and suggest that I NaL may also contribute to the cardiac dysfunction seen with SGK1 activation in vivo.
SGK1 Is Necessary and Sufficient for Heart Failure-Associated Alterations in Nav1.5
To understand the biochemical basis for the functional changes seen in I Na , we examined Nav1.5, the primary pore-forming subunit of the cardiac voltage-gated sodium channel complex. Although there was no change in overall cardiac Nav1.5 protein expression in SGK1-CA or SGK1-DN mice in comparison with WT, sucrose gradient fractionation 29 demonstrated that the subcellular distribution of Nav1.5 was altered by both TAC-HF and SGK1 activation in a similar way. In sham-operated WT mice, a large proportion of Nav1.5 was localized to lipid rafts with a modest amount of Nav1.5 in the heavy membrane (HM) fraction, likely comprising both intercalated disc and sarcoplasmic reticulum proteins (online-only Data Supplement Figure IXA, top) . TAC-HF and SGK1-CA hearts had similar increases in Nav1.5 in the HM fraction (online-only Data Supplement Figure IXA, middle and bottom) . In contrast, although the baseline Nav1.5 distribution in SGK1-DN hearts was similar to that in sham-operated WT, the increase in HM Nav1.5 seen in WT mice following TAC was markedly decreased in SGK1-DN hearts (online-only Data Supplement Figure IXB) . Figure 5 . SGK1 activation increases I NaL , whereas ranolazine normalizes APD and suppresses after-depolarizations in SGK1-CA cardiomyocytes. A, Representative normalized I NaL (% of peak) superimposed for WT and SGK1-CA cardiomyocytes. Inset shows that normalized I NaL was larger in SGK1-CA (nϭ6) than in WT cardiomyocytes (nϭ5). B, Superimposed APs in cardiomyocytes from WT and SGK1-CA mice before (baseline: solid line) and after ranolazine (dotted line) at 0.5-Hz pacing. Ranolazine (1 mol/L) normalized APD and suppressed EAD in SGK but did not affect APs in WT myocytes. C, Ranolazine (1mol/L) normalized APD 90 in SGK1-CA cardiomyocytes (*PϽ0.05, repeated-measures ANOVA), but did not affect APD 90 in WT cardiomyocytes. D, EADs and DADs were more frequent in SGK1-CA than in WT cardiomyocytes. Ranolazine (1 mol/L) reduced after-depolarizations in SGK1-CA cardiomyocytes (*PϽ0.05 by 2 test) to levels seen in WT cardiomyocytes. WT indicates wild type; SGK1, serum-and glucocorticoid-regulated kinase-1; CA, constitutively active; EAD, early after-depolarization; DAD, delayed after-depolarizations; AP, action potential; APD, action potential duration; Rano, ranolazine; and ANOVA, analysis of variance.
Thus, chronic SGK1 activation and TAC-HF increase trafficking of Nav1.5 to the HM fraction, whereas SGK1 inhibition blocks this response to TAC, suggesting SGK1 is both necessary and sufficient for these changes.
The increase in HM Nav1.5 would be expected to increase Na ϩ -channel surface availability. To test this directly, we used biotin to label surface-exposed proteins in neonatal rat ventricular myocytes expressing either SGK1-CA or green fluorescent protein, and selectively collected labeled surface proteins with an avidin-coupled column. As controls, the transmembrane protein, Glut 4, was labeled and recovered robustly from the surface of both green fluorescent proteinand SGK1-CA-expressing neonatal rat ventricular myocytes, while GSK3␤, a cytoplasmic protein, was not ( Figure 7A ). SGK1-CA expression increased the amount of biotin-labeled Nav1.5 in neonatal rat ventricular myocytes in comparison with green fluorescent protein-transduced cells ( Figure 7A ).
These data are consistent with the hypothesis that SGK1 activation increases the amount of Nav1.5 available at the cell surface.
Activation of SGK1 in renal tubular cells leads to phosphorylation of the ubiquitin ligase, Nedd4-2, 30,31 and decreased binding of the phospho-Nedd4-2 to the PY motif of E NaC , which increases surface expression and channel activity of E NaC . 32 Nav1.5 has also been shown to bind to Nedd4-2 via a conserved PY motif in its C-terminal tail, 33 and in a heterologous expression system, decreased binding of Nedd4-2 to Nav1.5 leads to increased Nav1.5 membrane expression. 34 We therefore examined if altered Nedd4-2 binding plays a role in Nav1.5 trafficking in response to TAC or SGK1 activation in vivo. Nedd4-2 coimmunoprecipitated with the Na channel in sham-operated WT hearts, and there was a marked decrease in Nedd4-2 binding to Na channels in TAC-HF and SGK1-CA hearts ( Figure 7B) . In contrast, SGK1-DN preserved Nedd4-2 binding to Na channels after TAC ( Figure 7C ). Thus, SGK1 activation appears both necessary and sufficient for the alterations in Nedd4-2 binding to Nav1.5 seen after TAC-HF. It seems likely that the observed alterations in Nedd4-2 binding and surface-available Na channel contribute to over-all increases in I Na but not the observed changes in channel gating and kinetics. To investigate other possible contributing mechanisms, we next examined whether SGK1 physically interacts with Nav1.5 protein. Immunoprecipitation experiments demonstrated that endogenous SGK1 protein binds the Na channel ( Figure 7D ). Because isoform-specific Na channel antibodies for immunoprecipitation are not available, it is possible that SGK1 binds not only Nav1.5, but also less abundant channel isoforms present in the heart. This physical association raised the possibility that SGK1 could phosphorylate Nav1.5. To begin to explore this possibility, we determined the SGK1 consensus target sequence by using a peptide library. 35 The preferred phosphorylation target sequence for SGK1 is similar to that for Akt (RKRRnS/T) but differs in the secondary amino acids (online-only Data Supplement Figure IXC) . Using the newly defined target motif in ScanSite, we identified 2 consensus sites in SCN5a (S483 and S664, both in the DI-II linker, which have been previously noted 11 ) and an additional novel but weaker consensus site (S1590) in the D4/S3 region (online-only Data Supplement Figure IXD) .
Overall, our data support the model that SGK1 is both necessary and sufficient for changes seen in Na-channel-Nedd4-2 binding and trafficking in TAC-HF. In addition, SGK1 directly associates with the sodium channel, which harbors multiple consensus target sequences for SGK1 phosphorylation. Cumulatively, these biochemical changes are likely to account for the electrophysiological alterations observed in SGK1-CA cardiomyocytes and mice. Determining the specific functional contributions of these proteinprotein interactions, and the putative SGK1 phosphorylation sites, as well, will be of interest for future studies.
Discussion
Heart failure and the ventricular arrhythmias that can accompany it are growing causes of morbidity and mortality around the world. 36 Acute activation of proximal phosphatidylinositol 3-kinase signaling has beneficial effects on cardiomyocyte survival and function 4, 5, 37 but is paradoxically increased in heart failure and diabetes, 7 raising the possibility that chronic activation of these initially compensatory pathways may become maladaptive. In this context, we investigated the role of SGK1, a serine-threonine kinase that we had previously shown is activated early in pressure overload and acutely promotes cardiomyocyte survival. 5 We found that SGK1 phosphorylation is also increased in animal models of chronic heart failure and human dilated cardiomyopathy. In contrast, SGK1 was not altered in exercise-induced physiological hypertrophy.
TG mice with constitutive cardiac activation of SGK1 spontaneously developed several hallmarks of adverse ventricular remodeling including systolic and diastolic dysfunction, as well as susceptibility to ventricular arrhythmias. The proarrhythmic effects of SGK1 activation were linked to biochemical and functional changes in the cardiac sodium channel that culminated in action potential prolongation and after-depolarizations, as well as an increase in I NaL . APD prolongation and after-depolarizations were completely normalized by treatment with ranolazine at doses that block late . SGK1 activation is necessary and sufficient for alterations in cardiac sodium channel seen in failing hearts. A, Cardiomyocytes were infected with either Ad.SGK1-CA or Ad.GFP, and biotin labeled to tag surface (eg, Nav1.5, Glut4) but not cytoplasmic proteins (eg, GSK3␤). Biotin-labeled proteins were captured by using an avidin column and subjected to immunoblotting. SGK1-CA expression increased surface expression of Nav1.5. *PϽ0.05, nϭ3 independent experiments. B, Total heart lysates from WT (sham-operated), TAC-HF, or unoperated SGK1-CA mice were immunoprecipitated with a pan-Na ϩchannel antibody (SP-19). Immunoblotting with antibodies to Nav1.5 or Nedd4-2 showed a decrease in Nedd4-2 binding in TAC-HF and SGK1-CA hearts. C, Cardiac lysates from SGK1-DN transgenic or WT mice subjected to TAC or sham operation were immunoprecipitated with SP-19 and immunoblotted with the antibody-specific Nav1.5 or Nedd4-2 (bottom). The decrease in Nedd4-2 binding to Nav1.5 seen in failing WT hearts is completely prevented in SGK1-DN hearts after TAC. D, SGK1 directly associates with Nav1.5. Sodium channel was immunoprecipitated from heart lysates by using SP-19 or control IgG antibody-coupled columns and subjected to immunoblotting as labeled. but not peak I Na . Finally, SGK1-CA mice treated with ranolazine in vivo not only showed decreased ECG abnormalities and susceptibility to ventricular arrhythmias, but also had better cardiac function, suggesting that altered sodium flux, specifically increased I NaL , is an important contributor to both the electric and mechanical phenotypes seen with chronic SGK1 activation in the heart. Consistent with this hypothesis, human SCN5a mutations can cause not only arrhythmia, but also cardiomyopathy. 22, 38 However, it seems likely that other SGK1 targets also contribute to cardiac dysfunction and fibrosis. The genetic models described in this work should provide useful platforms for identification of such pathways and dissecting their functional contributions to the phenotypes observed. We also found that SGK1 activation led to biochemical changes in the sodium channel that recapitulated changes seen in TAC-induced heart failure and included reduced association with the ubiquitin ligase, Nedd4-2, and altered channel trafficking resulting in an increase of surfaceavailable Nav1.5. Conversely, inhibition of SGK1 in the SGK1-DN mice blocked the biochemical changes in Nav1.5 after TAC-HF, supporting the specificity of these findings and suggesting SGK1 is also necessary for at least some aspects of electric remodeling. SGK1 bound Nav1.5, and peptide mapping identified several candidate SGK1 targets in the sodium channel. Intriguingly, one of these is in a region important in channel inactivation gating 22 and adjacent to a site mutated (D1595H in the Domain IV/S3 region) in a cardiomyopathy syndrome associated with arrhythmias. 22, 38 Testing the functional role of these putative phosphorylation sites will be of interest for future studies.
Taken together, the current study underscores the importance of SGK1 in both cardiac dysfunction and arrhythmia. Other kinases are also important modulators of Nav1.5, including protein kinase A, 39 protein kinase C, 40 and calcium calmodulin-dependent kinase II, 41, 42 and, thus, the inhibition SGK1 alone may not fully protect against these phenotypes. Nevertheless, our genetic data suggest that inhibition of SGK1 warrants further investigation as a therapeutic target in these settings, in particular, given the success of therapeutically targeting kinases on other settings.
